Top Page
Ocumetics Technology Corp
(OTC)
Ocumetics Technology Corp (OTC) vs. iShares MSCI Canada ETF (EWC)
Ocumetics Technology Corp Business Overview & Revenue Model
Ocumetics Technology Corp Financial Statement Overview
| Breakdown | TTM | Mar 2025 | Mar 2024 | Mar 2023 | Jul 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -69.94K | -134.30K | -117.62K | -102.21K | -96.18K | 0.00 |
| EBITDA | -2.85M | -2.29M | -3.50M | -2.09M | -3.42M | -99.35K |
| Net Income | -4.24M | -3.02M | -3.64M | -2.22M | -598.19K | -172.49K |
Balance Sheet | ||||||
| Total Assets | 1.63M | 2.32M | 1.04M | 1.37M | 825.25K | 225.32K |
| Cash, Cash Equivalents and Short-Term Investments | 905.41K | 1.57M | 235.83K | 602.09K | 83.90K | 224.35K |
| Total Debt | 4.92M | 3.95M | 321.64K | 292.34K | 0.00 | 0.00 |
| Total Liabilities | 5.52M | 4.26M | 945.33K | 536.45K | 1.10M | 17.94K |
| Stockholders Equity | -3.88M | -1.94M | 91.10K | 837.40K | -270.50K | 207.38K |
Cash Flow | ||||||
| Free Cash Flow | -2.43M | -2.51M | -2.19M | -1.69M | -213.63K | -817.00 |
| Operating Cash Flow | -2.36M | -2.43M | -2.05M | -1.62M | -89.13K | -817.00 |
| Investing Cash Flow | -109.77K | -1.46M | -142.17K | -66.82K | -214.92K | 0.00 |
| Financing Cash Flow | 1.37M | 3.85M | 1.82M | 444.35K | 387.11K | 0.00 |
Ocumetics Technology Corp Technical Analysis
Ocumetics Technology Corp Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
62 Neutral | C$52.75M | 95.68 | 7.07% | ― | 5.29% | -29.02% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | C$21.55M | -5.28 | ― | ― | 28.59% | 23.46% | |
46 Neutral | C$21.86M | -29.60 | -31.12% | ― | 9.71% | -118.02% | |
44 Neutral | C$22.27M | -31.01 | ― | ― | ― | -41.53% | |
42 Neutral | C$40.36M | -1.50 | -181.70% | ― | 209.29% | 35.38% |
Ocumetics Technology Corp Corporate Events
Ocumetics Technology Corp. reported positive three-month postoperative results from the first group of patients in its first-in-human clinical study of its accommodating intraocular lens, with data meeting or exceeding internal benchmarks for safety, lens delivery, and distance vision performance. Patients who entered the trial with severe visual impairment, including some at levels consistent with legal blindness, achieved meaningful, “life-changing” improvements in daily visual function, reinforcing the clinical viability of the technology and significantly de-risking the company’s platform as it prepares for the next phase of surgeries. Incorporating surgeon feedback, Ocumetics has already refined its lens delivery mechanism and initiated multiple lens optimization initiatives, with manufacturing and testing of improved designs underway, positioning the company to advance into Group 2 procedures and build momentum in its development roadmap.
The most recent analyst rating on (TSE:OTC) stock is a Hold with a C$0.52 price target. To see the full list of analyst forecasts on Ocumetics Technology Corp stock, see the TSE:OTC Stock Forecast page.
Ocumetics Technology Corp. has proposed a forbearance agreement with holders of its up to $4 million secured convertible debentures issued in 2024, under which debentureholders would agree not to demand repayment or enforce their security until June 19, 2027, despite the instruments reaching maturity two years from issuance. The debentures, bearing 18% annual interest and convertible into common shares at $0.32 per share, are secured by a general security agreement on the company’s personal property, and in exchange for the forbearance, Ocumetics plans—subject to TSX Venture Exchange approval—to issue new share purchase warrants to debentureholders, with each warrant exercisable at $0.58 until the earlier of June 19, 2027, or full repayment of the indebtedness. The arrangement effectively extends Ocumetics’ breathing room on its high-interest debt while offering creditors additional equity-linked upside, a move that may help support the company’s capital structure as it advances development of its ophthalmic technologies.
The most recent analyst rating on (TSE:OTC) stock is a Sell with a C$0.57 price target. To see the full list of analyst forecasts on Ocumetics Technology Corp stock, see the TSE:OTC Stock Forecast page.
Ocumetics Technology Corp., a leader in next-generation ophthalmic technology, is restructuring its medical and clinical leadership as it advances its accommodating intraocular lens through early feasibility studies toward late-stage clinical development. The company will replace its single Chief Medical Officer role, currently held under a consulting agreement by Dr. Doyle Stulting, with a multi-member Scientific Advisory Committee composed of internationally recognized experts in ophthalmology, medical research, and lens science, to provide broader medical, clinical and regulatory oversight ahead of a planned pivotal FDA clinical trial expected in 2027, while acknowledging Dr. Stulting’s contributions and reaffirming its focus on executing its clinical and regulatory strategy for global commercialization.
The most recent analyst rating on (TSE:OTC) stock is a Hold with a C$0.58 price target. To see the full list of analyst forecasts on Ocumetics Technology Corp stock, see the TSE:OTC Stock Forecast page.
Ocumetics Technology Corp. has closed the first tranche of a brokered private placement and a concurrent non-brokered placement, raising total gross proceeds of approximately $1.02 million through the sale of 1,706,383 units at $0.60 per unit, each unit comprised of one common share and one warrant exercisable at $0.75 until late 2028. The funds are earmarked primarily to support the company’s first-in-human clinical trials, ongoing R&D and general corporate purposes, with the offering led by Centurion One Capital and involving participation by several directors, underscoring insider support as Ocumetics advances its clinical and commercialization trajectory in the ophthalmic technology space.
The most recent analyst rating on (TSE:OTC) stock is a Hold with a C$0.58 price target. To see the full list of analyst forecasts on Ocumetics Technology Corp stock, see the TSE:OTC Stock Forecast page.
Ocumetics Technology Corp. has amended the terms of its previously announced brokered private placement led by Centurion One Capital, now planning to issue up to 4,166,666 units at $0.60 per unit for gross proceeds of up to $2.5 million, with each unit comprising one common share and a three-year warrant exercisable at $0.75. The company has also granted the lead agent an option to sell an additional 625,000 units for up to $375,000, expects to close the financing around December 29, 2025 subject to regulatory approvals, and intends to use the proceeds primarily to fund first-in-human clinical trials, ongoing R&D and general corporate purposes, with potential insider participation under related-party transaction exemptions.
Ocumetics Technology Corp. has announced an optimized lens delivery system developed in collaboration with Medicel AG, a leader in ophthalmic device delivery systems. This enhancement, based on surgeon feedback from initial human implantations, aims to improve loading efficiency and streamline implantation procedures, facilitating the acceptance of Ocumetics’ intraocular lens as the company prepares for expanded clinical studies in early 2026. This development underscores Ocumetics’ commitment to advancing its accommodating intraocular lens technology, potentially impacting its market positioning and stakeholder engagement as it moves towards regulatory engagements and broader trials.
Ocumetics Technology Corp. has announced a brokered private placement led by Centurion One Capital to raise $2.5 million through the sale of units, each consisting of a common share and a warrant. The funds are intended to support the company’s first-in-human clinical trials, ongoing research and development, and general corporate purposes. This strategic move is expected to bolster Ocumetics’ financial position and advance its clinical initiatives, potentially enhancing its market presence in the medical technology sector.
Ocumetics Technology Corp. announced promising one-month results from its first-in-human clinical study of the Ocumetics Accommodating Intraocular Lens. The initial group of patients showed significant improvement in vision, surpassing expectations with Corrected Distance Visual Acuity ranging from 20/32 to 20/25. These results reinforce the potential of the Ocumetics Lens to restore vision without corrective lenses and support the company’s advancement to the next phases of clinical trials.